May 23, 2006
EnVivo Expands Management Team as Company Prepares First Drugs for Clinical Trials
June 27, 2005
EnVivo Appoints Kees Been as Chief Executive Officer
February 01, 2005
Methylgene and EnVivo sign HDAC Collaboration Agreement
November 09, 2004
EnVivo Pharmaceuticals Secures $23 Million Series B Funding
August 17, 2004
EnVivo Announces Hiring of Vice President of Chemistry
July 19, 2004
MethylGene and EnVivo Pharmaceuticals to collaborate in Neurodegenerative Diseases
December 05, 2003
EnVivo Appoints Several Leaders to Its Scientific Advisory Board
November 17, 2003
EnVivo Announces Key Additions to Its Management Team
October 27, 2003
EnVivo Pharmaceuticals Has Moved to Watertown, Massachusetts
October 06, 2002
EnVivo Pharmaceuticals Closes $14.7M Series A Round Led by Fidelity BioSciences Group
October 01, 2002
EnVivo Pharmaceuticals Awarded NIH Grant to Develop Technology for CNS Drug Discovery
Huntington’s Disease Summit – July 29, 2005
- EnVivo hosted a summit on development of therapies for Huntington’s Disease that was attended by leading researchers and clinicians for Huntington’s Disease.
Therapeutic Strategies against Neurodegenerative Conditions (TSANC) – October 10-11, 2005, Boston, MA
- Dr. Gerhard Koenig, CSO will give a presentation titled “Building a Pipeline of Novel Therapeutics for Neurodegenerative Diseases Using Phenotypic Screening”.
Mass Opportunities: A Biotechnology Investment Conference – November 3, 2005, Boston, MA
- Kees Been, CEO will present at the upcoming Mass Opportunities conference.
BIO-Europe 2005 – November 7-9, 2005, Dresden, Germany
- Kees Been, CEO will present at the upcoming BIO-Europe conference.